Kura Oncology (KURA) Free Cash Flow (2023 - 2026)
Kura Oncology has reported Free Cash Flow over the past 4 years, most recently at -$86.0 million for Q1 2026.
- Quarterly Free Cash Flow fell 19.06% to -$86.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$84.5 million through Mar 2026, down 176.4% year-over-year, with the annual reading at -$70.7 million for FY2025, 152.82% down from the prior year.
- Free Cash Flow was -$86.0 million for Q1 2026 at Kura Oncology, down from $112.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $268.8 million in Q4 2024 and troughed at -$86.0 million in Q1 2026.
- The 4-year median for Free Cash Flow is -$35.9 million (2023), against an average of -$11.4 million.
- Year-over-year, Free Cash Flow surged 883.01% in 2024 and then plummeted 86.24% in 2025.
- A 4-year view of Free Cash Flow shows it stood at -$34.3 million in 2023, then surged by 883.01% to $268.8 million in 2024, then plummeted by 58.08% to $112.7 million in 2025, then crashed by 176.32% to -$86.0 million in 2026.
- Per Business Quant, the three most recent readings for KURA's Free Cash Flow are -$86.0 million (Q1 2026), $112.7 million (Q4 2025), and -$80.9 million (Q3 2025).